Number of pregnancies and ovariectomy modify mammary carcinoma development in transgenic HER-2/neu female mice

Cancer Letters

Volumn 193, Issue 1, 2003, Pages 49-55

  Anisimov, Vladimir N ^a   Popovich, Irina G ^a   Alimova, Irina N ^a   Zabezhinski, Mark A ^a   Semenchenko, Anna V ^b   Yashin, Anatoli I ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b MAX PLANCK INSTITUTE FOR DEMOGRAPHIC RESEARCH   (Germany)

Author keywords

HER 2 neu transgenic mice; Mammary carcinoma; Ovariectomy; Pregnancy

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HOMOZYGOSITY; LIFESPAN; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; ONCOGENE NEU; OVARIECTOMY; PREGNANCY; PRIORITY JOURNAL; SURVIVAL TIME; TRANSGENIC MOUSE; TUMOR VOLUME;

ANIMALIA; MUS MUSCULUS;

EID: 0037431071     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00721-8     Document Type: Article

References (29)

1. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur. J. Cancer. 37:2001;S4-S66.
2. Reinolds T.M., Wierzbicki A.S. Survival and reduction in mortality from breast cancer: improvements in survival may be an illusion. Br. Med. J. 321:2000;1471-1472.
3. Kesley J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer. Epidemiol. Rev. 15:1993;36-47.
4. Lambe M., Hsieh C.-C., Trichopoulos D., Ekbom A., Pavia M., Adami H.-O. Transient increase in the risk of breast cancer after giving birth. N. Engl. J. Med. 331:1994;5-9.
5. Hsieh C.-C., Chan H.-W., Lambe M., Ekbom A., Adami H.-O., Trichopoulos D. Dose age at the last birth affect breast cancer risk? Eur. J. Cancer. 32A:1996;118-121.
6. Robertson C., Primic-Zakeli M., Boyle P., Hsien C.-C. Effect of parity and age at delivery on breast cancer risk in Slovenian women aged 25-54 years. Int. J. Cancer. 73:1997;1-9.
7. Liu Q., Wuu J., Lambe M., Hsieh S.F., Ekbom A., Hsieh C.C. Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control. 13:2002;299-305.
8. Deringer M.K. Occurence of tumors, particularly mammary tumors, in agent-free strain C3HeB mice. J. Natl. Cancer Inst. 22:1959;995-1001.
9. Andrechek E.R., Hardy W.R., Siegel P.M., Rudnicki M.A., Cardiff R.D. Amplification of the neu/erbB-2 oncogene in a mouse model mammary tumorigenesis. Proc. Natl. Acad. Sci. USA. 97:2000;3444-3449.
10. Nunes R.A., Harris L.N. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin. Breast Cancer. 3:2002;125-135.
11. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognsotic value of c-erbB2 expression in breast cancer. J. Surg. Oncol. 79:2002;216-223.
12. Kato T., Kameoka S., Kimura T., Nishikawa T., Kobayashi M. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Anticancer Res. 22:2002;1097-1103.
13. Treurniet H.F., Rookus M.A., Peterse H.L., Hart A.A., van Leeuwen F.E. Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor. Cancer Res. 52:1992;2344-2345.
14. Chan R., Muller W.J., Sigel P.M. Oncogenic activating mutations in the neu/erbB-2 oncogene involved in the induction of mammary tumors. Ann. N.Y. Acad. Sci. 889:1999;45-51.
15. Weinstein E.J., Kitsberg D.I., Leder P. A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene. Mol. Med. 6:2000;4-16.
16. Anisimov V.N., Khavinson V.K., Provinciali M., Alimova I.N., Baturin D.A., Popovich I.G., Zabezhinski M.A., Imyanitov E.N., Mancini R., Franceschi C. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int. J. Cancer. 101:2002;7-10.
17. Turusov V.S., Mohr U. IARC Sci. Publ. No. 111 Pathology of Tumours in Laboratory Animals: Vol. I. Tumours of the Mouse. 2nd Edition:1994;IARC, Lyon.
18. Cardiff R.D., Anver M.R., Gusterson B.A., Hennighausen L., Jensen R.A., Merino M.J., Rehm S., Russo J., Tavassoli F.A., Wakefield L.M., Ward J.M., Green J.E. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 21:2000;968-988.
19. Cox D.R., Oakes D. Analysis of Survival Data. 1996;Chapman & Hall, London.
20. Gauss System and Graphic Manual. 1994;Aptech Systems, Inc, Maple Valley.
21. Jones F.E., Stern D.F. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene. 18:1999;3481-3490.
22. Clausse N., Smith R., Calberg-Bacq C.M., Peters G., Dickson C. Mouse mammary-tumor virus activates Fgf-2/Int-2 less frequently in tumors from virgin than from parous mice. Int. J. Cancer. 55:1993;157-163.
23. Schwartz M.S., Smith G.H., Medina D. The effect of parity, tumor latency and transplantation on the activation of int loci in MMMTV-induced transplanted C3H mammary pre-neoplasias and their tumors. Int. J. Cancer. 51:1992;805-811.
24. D'Cruz C.M., Moody S.E., Master S.R., Hartman J.L., Keiper E.A., Imielinski M.B., Cox J.D., Wang J.W., Ha S.I., Keister B.A., Chodosh L.A. Persistent parity-induced changes in growth factors, TGF-β3, and differentiation in the rodent mammary gland. Mol. Endocrinol. 16:2002;2034-2051.
25. Lazar H., Baltzer A., Gimmi C., Marti A., Jaggi R. Over-expression of ErbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis. Int. J. Cancer. 85:2000;578-583.
26. Wang B., Kennan W.S., Yasukawa-Barnes J., Lindstrom M.J., Gould M.N. Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy. Cancer Res. 52:1992;4102-4105.
27. Hewitt S.C., Bocchinfuso W.P., Zhai J., Koonce L., Clarc J., Myers P., Korach K.S. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Cancer Res. 62:2002;2790-2805.
28. Blanchard D.K., Hartmann L.C. Phrophylactic surgery for women at high risk for breast cancer. Clin. Breast Cancer. 1:2000;127-134.
29. Grann V.R., Jacobson J.S., Thomason D., Hershman D., Heitjan D.F., Neugut A.I. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J. Clin. Oncol. 20:2002;2520-2529.